Valiant Laborato

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0JWS01017
  • NSEID: VALIANTLAB
  • BSEID: 543998
INR
124.71
2.12 (1.73%)
BSENSE

Sep 18, 03:30 PM

BSE+NSE Vol: 1.74 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Albert David
Valiant Laborato
Kilitch Drugs
Medicamen Biotec
Zim Laboratories
Amanta Healthcar
Bafna Pharma.
Haleos Labs Limi
Aptus Pharma
Transchem
Influx Health.

Why is Valiant Laboratories Ltd ?

1
Weak Long Term Fundamental Strength with a -7.44% CAGR growth in Operating Profits over the last 5 years
  • The company has been able to generate a Return on Capital Employed (avg) of 0.05% signifying low profitability per unit of total capital (equity and debt)
2
With a growth in Net Profit of 1098.86%, the company declared Outstanding results in Jun 26
  • The company has declared positive results for the last 2 consecutive quarters
  • NET SALES(Q) Highest at Rs 115.29 cr
  • PBDIT(Q) Highest at Rs 29.26 cr.
  • OPERATING PROFIT TO NET SALES(Q) Highest at 25.38%
3
With ROE of -1.1, it has a Very Expensive valuation with a 2.2 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 44.29%, its profits have risen by 1587%
4
Despite the size of the company, domestic mutual funds hold only 0% of the company
  • Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Valiant Laborato should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Valiant Laborato for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Valiant Laborato
44.29%
0.80
55.16%
Sensex
-10.5%
-0.78
13.50%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
0.65%
EBIT Growth (5y)
-7.44%
EBIT to Interest (avg)
5.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.04
Sales to Capital Employed (avg)
0.68
Tax Ratio
34.77%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-0.58%
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
43
Industry P/E
37
Price to Book Value
2.20
EV to EBIT
28.03
EV to EBITDA
20.97
EV to Capital Employed
2.15
EV to Sales
2.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.10%
ROE (Latest)
-1.06%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

37What is working for the Company
NET SALES(Q)

At Rs 115.29 cr has Grown at 94.2% (vs previous 4Q average

PAT(Q)

At Rs 21.10 cr has Grown at 2673.2% (vs previous 4Q average

PBDIT(Q)

Highest at Rs 29.26 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 25.38%

PBT LESS OI(Q)

Highest at Rs 25.33 cr.

EPS(Q)

Highest at Rs 3.89

-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Valiant Laborato

Net Sales - Quarterly
At Rs 115.29 cr has Grown at 94.2% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 59.37 Cr
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 25.33 cr has Grown at 6679.2% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs -0.39 Cr
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 21.10 cr has Grown at 2673.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs -0.82 Cr
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 115.29 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 29.26 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 25.38%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 25.33 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 21.10 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 3.89
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)